Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

DiaMedica Therapeutics (DMAC) Accumulated Depreciation & Amortization (2017 - 2026)

DiaMedica Therapeutics filings provide 10 years of Accumulated Depreciation & Amortization readings, the most recent being $159000.0 for Q1 2026.

  • Quarterly Accumulated Depreciation & Amortization rose 30.33% to $159000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $159000.0 through Mar 2026, up 30.33% year-over-year, with the annual reading at $150000.0 for FY2025, 31.58% up from the prior year.
  • Accumulated Depreciation & Amortization hit $159000.0 in Q1 2026 for DiaMedica Therapeutics, up from $150000.0 in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $159000.0 in Q1 2026 and bottomed at $62000.0 in Q1 2022.
  • Average Accumulated Depreciation & Amortization over 5 years is $104117.6, with a median of $100000.0 recorded in 2023.
  • The largest annual shift saw Accumulated Depreciation & Amortization increased 6.19% in 2024 before it surged 34.95% in 2025.
  • DiaMedica Therapeutics' Accumulated Depreciation & Amortization stood at $80000.0 in 2022, then grew by 25.0% to $100000.0 in 2023, then grew by 14.0% to $114000.0 in 2024, then skyrocketed by 31.58% to $150000.0 in 2025, then grew by 6.0% to $159000.0 in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Accumulated Depreciation & Amortization are $159000.0 (Q1 2026), $150000.0 (Q4 2025), and $139000.0 (Q3 2025).